NCT01993498Recruiting
Chronic Toxicities Related to Treatment in Patients With Localized Cancer
A Prospective Cohort to Investigate Survivorship Issues in Patients With Early Cancer
Source: ClinicalTrials.gov · Last updated 18 Oct 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The aims of the cohort will be to quantify impact of cancer treatments toxicities , and to generate predictors of chronic toxicity in patients with non-metastatic cancer. Study of the original cohort will be focused on localized breast cancer patients, other localisation in non-metastatic setting will be explored furtherwise, fist of all in lung cancer. The project will include four specific aims : 1. To develop a database of chronic treatment related toxicity in a cohort of 14750 women with stage I-III breast cancer (= non metastatic), whatever these treatments are (surgery; radiation therapy; chemotherapy …) 2. To describe incidence, clinical presentation, and outcome of chronic toxicities. 3. To describe the psychological, the social and the economic impacts of chronic toxicities. 4. To generate predictors for chronic toxicities in order to prevent them, based upon biological criteria. The expected impact of these toxicities, when identified, will be to improve quality of life and to decrease health cost, by the early identification of patients at high risk of toxicity. Such early identification could lead to prevent toxic effect by: a. developing prevention strategies, b. substituting toxic treatment by a non (less) toxic one. Also, such cohort will offer a quantification of the impact of treatment toxicity, that could be further used to quantify medical usefulness of strategies that aim at decreasing treatment toxicities (implementation of predictive biomarker for resistance, cytotoxic-free regimen etc…)
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 14750 (estimated)
- First submitted
- 17 Oct 2013
- Start date
- 20 Feb 2012
- Primary completion date
- 31 Mar 2034
- Lead sponsor
- UNICANCER
- Diseases
- Lung cancer
- NCT number
- NCT01993498
What you commit to
- Study type: Interventional
- Planned participants: 14750
- From 20 Feb 2012 to the primary completion date, 31 Mar 2034
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Already received treatment for breast cancer ongoing,
- Treatment already received for current lung cancer,
Other illness
- Metastatic breast cancer,
- Local recurrence of breast cancer,
- History of cancer within 5 years prior to entry into the trial other than basal cell skin or carcinoma in situ of the cervix,
- Metastatic lung cancer,
- Local relapse of lung cancer,
- History of cancer within 3 years prior to study entry other than basal cell cutaneous or epithelioma in situ of the cervix,
Other
- Blood transfusion performed for less than six months,
- Persons deprived of liberty or under supervision (including guardianship).
- CANTO - Lung
- Blood transfusion carried out less than 6 months ago,
- Persons deprived of liberty or under guardianship (including curatorship).
Who the study is looking for
- Women,
- Aged 18 years and over,
- With an invasive breast cancer diagnosed by cytology or histology,
- No clinical evidence of metastasis at the time of inclusion,
- Untreated including scored for breast cancer surgery in progress,
- Patient receiving a social security system,
- Patient mastering the French language,
- Free and informed consent for additional biological samples, different questionnaires and collecting information on resource usage.
- (Since february 2022) Patient :
- Age \< 45 years at diagnostic
- Or CT2-3, cN0-3, HER2+(RH+or RH-) or RH-HER2-
- Or Eligible to Pembrozilumab, Olaparib, TDM1, Abemaciclib or Ribociclib
- Aged 18 years and over, Having lung cancer diagnosed by cytology or histology or suspected cancer of the lung,
- Tumor cTX to cT4, cN0-3,
- No clinical evidence of metastasis at the time of inclusion (patients with metastases on extension assessment within 6 months following diagnosis will be removed from the study),
- Eligible for curative treatment by surgery or radiotherapy \* (note patients treated with exclusive chemotherapy, exclusive radiotherapy or exclusive stereotactic radiotherapy will be out of study)
- Lack of treatment received for current lung cancer, including surgical treatment
- Patient benefiting from a social protection scheme,
- Patient mastering the French language,
- Free and informed consent for additional biological samples, the different questionnaires and the collection of information on resource consumption.
Criteria the registry did not label
- CANTO - Breast
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Gustave Roussy Coordinator of this site? Confirm its status | Villejuif | France | Recruiting |
Related publications
- Prognostic value of lymphopenia in early breast cancer: learnings from the prospective CANTO cohort.Breast Cancer Res · 2026 · PMID 42265714
This page is information, not medical advice. Discuss any trial with your doctor.